Year: 2025
Type: article
Abstract: Advances in immunotherapy, targeted therapy, and biomarker-driven treatment strategies are transforming the management of resectable non–small cell lung cancer (NSCLC). During JADPRO Live 2024, presenters discussed the latest advancements in perioperative and adjuvant therapies, biomarker testing, and future directions in NSCLC treatment.
Author: Danielle Fournier, DNP, APRN, AGPCNP-BC, AOCNP
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4409003681